Research reveals GLP-1 and SGLT-2 medications may lower COPD exacerbation risk in diabetes, offering new hope for dual condition management.

There are certain risk factors for COPD, including obesity and having type 2 diabetes. A new study has found that people who have type 2 diabetes who are treated with GLP-1 and SGLT-2 medications ...

The Institute for Clinical and Economic Review (ICER) released a report on Monday assessing the clinical effectiveness and ...

For patients with type 2 diabetes (T2D) and chronic obstructive pulmonary disorder (COPD), sodium-glucose cotransporter-2 ...

Vantage Market Research is pleased to announce the publication of its latest report, Asthma and COPD Drugs Market. This ...

New Delhi: Cancer patients facing prohibitive treatment costs in India can hope for relief: the nation's top drugmakers have ...

GSK (GSK) announced that the China National Medical Products Administration, CNMPA, has accepted for review the new drug application for the ...

A recent study found that participants who practice mindfulness reported significantly less severe symptoms of anxiety, ...

Share on Pinterest GLP-1 and SGLT-2 drugs may be the best treatments for people with type 2 diabetes and COPD. Image credit: Visual Vic/Getty Images. Researchers estimate the number of people ...

“These findings suggest that SGLT-2is and GLP-1 RAs may be preferable to DPP4is when deciding among glucose-lowering medications for patients with T2D and active COPD,” the authors write.